FIELD: biotechnology.
SUBSTANCE: claimed invention: an antigenic receptor for providing an immune response to cancer cells expressing a tumour antigen, the receptor contains a first peptide chain and a second peptide chain, a recombinant CD8+ T host cell expressing the antigen receptor and a method for its production, a nucleic acid, a pharmaceutical formula and method for treating cancer.
EFFECT: invention allows to use it in the treatment of malignant tumours by targeting cells expressing the antigen on the cell surface, where the tumour antigen is claudin 6.
13 cl, 18 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIGEN RECEPTORS AND THEIR APPLICATIONS | 2018 |
|
RU2794945C2 |
| AGENTS FOR TREATMENT OF CLAUDIN EXPRESSING CANCER DISEASES | 2013 |
|
RU2678127C2 |
| ANTIBODIES USEFUL IN DIAGNOSING CANCER | 2018 |
|
RU2815883C1 |
| ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER DIAGNOSIS | 2013 |
|
RU2661772C2 |
| MODIFIED CELLS WITH CHIMERIC ANTIGEN RECEPTOR FOR TREATING CANCER EXPRESSING CLDN6 | 2020 |
|
RU2826058C2 |
| CHIMERIC ANTIBODY/T-CELL RECEPTOR STRUCTURES AND THEIR APPLICATIONS | 2016 |
|
RU2767209C2 |
| COMBINED THERAPY WITH CLAUDINE 18.2 ANTIBODIES FOR CANCER TREATMENT | 2014 |
|
RU2699549C2 |
| COMBINATION THERAPY USING ANTIBODIES TO CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2013 |
|
RU2789478C2 |
| COMBINED THERAPY BASED ON TUMOUR-TARGETED IMMUNOCYTOKINES CONTAINING VARIANT IL-2, AND ANTIBODIES TO HUMAN PD-L1 | 2015 |
|
RU2710354C2 |
| CHIMERIC ANTIGENIC RECEPTORS AIMED AT ANTIGEN OF AGING OF B-CELLS | 2016 |
|
RU2706582C2 |
